Larimar Therapeutics (Larimar Therapeutics) FCF Yield % : -7.37 (As of May. 13, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Larimar Therapeutics's Trailing 12-Month Free Cash Flow is $-33.46 Mil, and Market Cap is $454.26 Mil. Therefore, Larimar Therapeutics's FCF Yield % for today is -7.37%.

The historical rank and industry rank for Larimar Therapeutics's FCF Yield % or its related term are showing as below:

LRMR' s FCF Yield % Range Over the Past 10 Years
Min: -29.11 Med: 0 Max: 0
Current: -7.37

LRMR's FCF Yield % is ranked better than
63.86% of 1555 companies
in the Biotechnology industry
Industry Median: -14.28 vs LRMR: -7.37

Larimar Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Larimar Therapeutics FCF Yield % Historical Data

The historical data trend for Larimar Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics FCF Yield % Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-12.84

-22.21

-15.48

-16.83

Larimar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial														-14.93	-15.41	-21.75	-21.22	-18.71

Competitive Comparison of Larimar Therapeutics's FCF Yield %

For the Biotechnology subindustry, Larimar Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's FCF Yield % falls into.

Larimar Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Larimar Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-33.623	/	199.786405
	=	-16.83%

Larimar Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-9.343	*	4	/	199.786405
	=	-18.71%

Larimar Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Larimar Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

ZA71:Germany

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Executives

Gopi Shankar	officer: Chief Development Officer	C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton	officer: Chief Medical Officer	2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon	director, officer: President and CEO	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano	officer: Chief Financial Officer	220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton	director	211 STUYVESANT AVE, RYE NY 10580
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc	10 percent owner	150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017